key: cord-0866272-y0m2jhze authors: Ebanks, Daniel; Faustini, Sian; Shields, Adrian; Parry, Helen; Moss, Paul; Plant, Tim; Richter, Alex; Drayson, Mark title: Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays date: 2021-07-26 journal: J Infect DOI: 10.1016/j.jinf.2021.07.020 sha: 40f0e942afc33d39bd2b670d1185812835d0af60 doc_id: 866272 cord_uid: y0m2jhze nan The Coronavirus 2 (SARS-CoV-2) pandemic continues to affect almost every country in the world (1) . In the UK, two main vaccines have formed the basis of the national immunisation strategy: the AstraZeneca ChAdOx1 nCoV-19 vaccine (AZ) (2) and the Pfizer-BioNtech COVID-19 vaccine (PFZ) (3) . Both elicit immune responses targeting the viral spike protein and both have been shown to reduce the incidence of severe disease in early trials (2, 3) . With the emergence of several variants of concern (VOC) such as the B.1.1.7 (United Kingdom -Alpha), that have increased transmissibility (4, 5) , it is necessary to understand whether current vaccines will provide protection against VOC. We have shown the use of the AbC-19™ rapid IgG LFT (Abingdon Health) can successfully determine seropositivity for SARS-CoV-2 in all 40 individuals aged 28-81 years of age tested following second dose of vaccine, and 8/10 health care workers following natural infection. IgG antibody levels were greatest after PFZ vaccination (median age 47 years) and lowest after natural infection (median age Exploring the realworld effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-) WHO World Health Organisation. Tracking SARS-CoV-2 variants. ONLINE. 2021 COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients We thank the staff of University Hospitals Birmingham NHS Foundation Trust who kindly volunteered for this study. We would also like to thank the research staff of the Birmingham Wellcome NIHR Clinical Research Facility who undertook the staff facing assessments. We would like to thank colleagues at the Clinical Immunology Service for overseeing recruitment, sample processing and LFA scoring. Not applicable. Not applicable. None. All authors have contributed to the manuscript. None. None, paper is of interest to patients and public in light of current pandemic. An observational study. The author affirms the manuscript is an honest accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Drayson, Plant and University of Birmingham own stock min Abingdon Health